


performing network for non-conventional  
Europe — Thierry Stora, CERN, PRISMAP Coordinator



○ Production facility + Medical facility > Future facility



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP)



[www.prismap.eu](http://www.prismap.eu)




[info@prismap.eu](mailto:info@prismap.eu)



[@MedRadionuclide](https://twitter.com/MedRadionuclide)



PRISMAP Project



Prismap

## European Medical Radionuclides Programme

The European medical  
radionuclide programme  
for the production of  
high-purity radionuclides  
by mass separation

We are building the most extensive and pe  
medical radionuclides ever imagined in E

GSI Helmholtzzentrum für  
Schwerionenforschung GmbH

CHUV Centre hospitalier  
universitaire vaudois

SCIPROM Sàrl

SCK CEN Belgian Nuclear  
Research Centre

KU Leuven Katholieke  
Universiteit Leuven

NPL National Physical Laboratory

GANIL Grand Accélérateur  
National d'Ions Lourds

Groupe d'intérêt public  
ARRONAX

CERN European organization  
for nuclear research

IST-ID Associação do Instituto  
Superior Técnico para a  
Investigação e Desenvolvimento

ILL Institut Max von  
Laue - Paul Langevin

CEA Commissariat à l'énergie  
atomique et aux énergies alternatives

> FAIR

+ AGORA

○ BR2

+ NURA

> MYRRHA

> SPIRAL 2

○ ARRONAX

○ MEDICIS

○ RHF

> JHR



## WHAT IS PRISMAP

Radionuclide therapy and molecular imaging are widely used at hospitals for new promising medical procedures. They can drastically improve the outcome for many medical conditions, and enable treating disseminated cancer in particular.

However, their effective development has long been limited by the difficult access to radionuclides not yet commercially available. With PRISMAP, the European medical radionuclide programme, this is about to change.

## OUR OBJECTIVES

- Provide transnational access to new radionuclides and new purity grades for medical research
- Create a common entry port and web interface to the starting research community
- Enhance clarity and regulatory procedures to enhance research with radiopharmaceuticals
- Improve the delivered radionuclide data and regulation, along with biomedical research capacity
- Ensure sustainability of PRISMAP on the long term

## OUR CONSORTIUM AND INFRASTRUCTURE

We federate a European consortium of the key intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical and healthcare research institutes in the active translation of the emerging radionuclides into medical diagnosis and treatment.

Our expertise in the production and dispatch of non-conventional radionuclides and our integration in a joint network will allow to provide new radionuclides and reach new purity grades for medical research.

The research centres and hospitals of PRISMAP all demonstrate key competences in translational research and are crucial to foster a new research era based on emerging medical radionuclides.

**Find the full portfolio of our available medical radionuclides on our website or by scanning this QR code.**

[www.prismap.eu/portfolio](http://www.prismap.eu/portfolio)



## WHAT CAN WE DO FOR YOU?

- Production and delivery of high-purity grade radionuclides for medical research
- Access to a selection of medical research laboratories to perform the associated research
- Selection of preclinical research techniques fully performed as a service

To get access to PRISMAP radionuclides and related services, users are invited to submit project applications.

## WHO CAN APPLY?

- To promote cross-border access, only transnational access is granted.
- Access for user groups with a majority of users not working in an EU or associated country is limited.
- Users need to be affiliated to an academic research institution, to a non-academic research institution, to a research hospital, or to the research department of an SME.
- The research project must relate to the use of radionuclides in medical applications.
- Only user groups that are allowed to disseminate the results which they have generated under the project may benefit from the access, unless the users are working for SMEs.

## EVALUATION PROCEDURE

Projects will be evaluated based on eligibility and scientific merit through independent peer review by a User Selection Panel consisting of six members of the PRISMAP consortium and six external international scientific experts.

Priority will be given to:

- Research teams who have not previously used the services
- Projects with potential to attract additional financial support
- Research teams who are working in countries where the services sought are not readily available

**Submit your project for our biannual calls via our online application form.**

**Read our guide for applicants for all the practical information you may need.**

[www.prismap.eu/access](http://www.prismap.eu/access)

